SCHEMBL2177733

SCHEMBL2177733

COc1cc2nccc(Oc3ccc(CC(=O)Nc4nc(C)no4)cc3)c2cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.63
CSF1R P07333 5/20 0.63
PDGFRB P09619 5/20 0.63
FLT3 P36888 5/20 0.63
MET P08581 7/20 0.61
FLT4 P35916 2/20 0.60
PDGFRA P16234 9/20 0.57
KIT P10721 3/20 0.57
RET P07949 2/20 0.56
DDR1 Q08345 2/20 0.56
AURKB Q96GD4 2/20 0.53
AURKA O14965 1/20 0.51
RIPK2 O43353 1/20 0.51
ABCB11 O95342 1/20 0.51
ABL1 P00519 1/20 0.51
EGFR P00533 1/20 0.51
ERBB2 P04626 1/20 0.51
NTRK1 P04629 1/20 0.51
LCK P06239 1/20 0.51
PGR P06401 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176626 0.84 PDGFRB (0.81) KDRCSF1RPDGFRBFLT3MET
SCHEMBL2173815 0.82 MET (0.68) KDRCSF1RPDGFRBFLT3MET
SCHEMBL2173631 0.82 KDR (0.69) KDRCSF1RPDGFRBFLT3MET
SCHEMBL2176128 0.80 MET (0.64) KDRCSF1RPDGFRBFLT3MET
SCHEMBL2175642 0.80 CSF1R (0.69) KDRCSF1RPDGFRBFLT3MET
SCHEMBL21301531 0.79 MET (0.85) KDRCSF1RPDGFRBFLT3MET
SCHEMBL31324673 0.79 MET (0.85) KDRCSF1RPDGFRBFLT3MET
SCHEMBL22104148 0.79 PDGFRA (0.74) KDRCSF1RPDGFRBFLT3MET
SCHEMBL22104153 0.79 PDGFRA (0.71) KDRCSF1RPDGFRBFLT3MET
SCHEMBL2173585 0.79 MET (0.70) KDRCSF1RPDGFRBFLT3MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 KDR 2277/4885CSF1R 818/4885PDGFRB 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.